All In Biotech

Drug Trial Radar · NCT03709706

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

34

Actual

Start

Dec 31, 2018

Primary completion

Jun 27, 2022

Study completion Nov 4, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.

Conditions

  • Neoplasms

Interventions

  • Lete-celDrug

    lete-cel will be administered to eligible participants.

  • PembrolizumabDrug

    Pembrolizumab will be administered to eligible participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 10 months
  2. Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)Time frame: Up to approximately 10 months
  3. Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events Based on Maximum Severity GradesTime frame: Up to approximately 10 months
  4. Number of Participants With AEs Leading to Dose DelaysTime frame: Up to approximately 10 months
  5. Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to approximately 10 months

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Duarte, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Stanford, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Groningen, Netherlands

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Utrecht, Netherlands

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.